<DOC>
	<DOCNO>NCT01318733</DOCNO>
	<brief_summary>A long-term , open-label , non-comparative safety efficacy study CD07805/47 gel 0.5 % daily subject moderate severe facial erythema associate rosacea .</brief_summary>
	<brief_title>Study CD07805/47 Topical Gel Subjects With Facial Erythema Associated With Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Erythema</mesh_term>
	<criteria>Male female least 18 year age older . A clinical diagnosis facial rosacea . A Clinician Erythema Assessment ( CEA ) score ≥3 Screening Baseline ( prior study drug application ) . A Patient Self Assessment ( PSA ) score ≥3 Screening Baseline ( prior study drug application ) . Particular form rosacea ( rosacea conglobata , rosacea fulminans , isolated rhinophyma , isolated pustulosis chin ) concomitant facial dermatosis similar rosacea perioral dermatitis , demodicidosis , facial keratosis pilaris , seborrheic dermatitis , acute lupus erythematosus , actinic telangiectasia . Current diagnosis Raynaud 's syndrome , thromboangiitis obliterans , orthostatic hypotension , severe cardiovascular disease , cerebral coronary insufficiency , renal hepatic impairment , scleroderma , Sjögren 's syndrome , depression . Previous refractive eye surgery photorefractive keratectomy ( PRK ) , laserassisted subepithelial keratectomy ( LASEK ) , laserassisted situ keratomileusis ( LASIK ) . Current treatment monoamine oxidase ( MAO ) inhibitor . Current treatment barbiturate , opiate , sedative , systemic anesthetic , alphaagonists . Less 3 month stable dose treatment tricyclic antidepressant , cardiac glycoside , beta blocker antihypertensive agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Rosacea</keyword>
</DOC>